A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants

Safety Clinical Trial

Official title:

A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01399853
• Other study ID #: JSVCT005
• Status: Completed
• Phase: Phase 2
• First received: July 19, 2011
• Last updated: May 29, 2012
• Start date: July 2011
• Est. completion date: May 2012

Study information

• Verified date: May 2012
• Source: Jiangsu Province Centers for Disease Control and Prevention
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Hand, foot, and mouth disease (HFMD) is a common viral illness in infants and children caused by viruses that belong to the enterovirus genus of the picornavirus family. Although most HFMD cases do not result in serious complications, outbreaks of HFMD caused by enterovirus 71 (EV71) can present with a high rate of neurological complications, including meningoencephalitis, pulmonary complications, and can even cause infant death. HFMD caused by EV71 has become a major emerging infectious disease in Asia and the highly pathogenic potential of EV71 clearly requires the attention of world medical community.

The phase I study of inactivated vaccine (vero cell) against EV71 has completed last month in Jiangsu Province in China. The data from the phase I study suggested that the inactivated EV71 vaccine had a clinically acceptable safety and good immunogenicity for healthy Chinese children and infants. In order to provide more evidence for the immunogenicity of the vaccine, to further explore the probable immunizing dose and the safety profile of this vaccine, a phase II clinical trial is planed to conduct.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1200
• Est. completion date: May 2012
• Est. primary completion date: November 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 6 Months to 36 Months

Eligibility

Inclusion Criteria:

For children group (aged from 12-36 months):

• Healthy children aged from 12 to 36 months old as established by medical history and clinical examination

• The subjects' guardians are able to understand and sign the informed consent

• Had never received the vaccine against EV71

• Subjects who can and will comply with the requirements of the protocol

• Subjects with temperature <=37.0°C on axillary setting

For infants group (aged from 6-11 months):

• Healthy infants aged from 6 to 11 months old as established by medical history and clinical examination

• The subjects' guardians are able to understand and sign the informed consent

• Had never received the vaccine against EV71

• Subjects who can and will comply with the requirements of the protocol

• Subjects with temperature <=37.0°C on axillary setting

Exclusion Criteria:

For children group (aged from 12-36 months):

• Subject who has a medical history of HFMD

• <= 37 weeks gestation

• Subjects with a birth weight <2.5 kg

• Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine

• Family history of seizures or progressive neurological disease

• Family history of congenital or hereditary immunodeficiency

• Severe malnutrition or dysgenopathy

• Major congenital defects or serious chronic illness, including perinatal brain damage

• Autoimmune disease

• Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws

• Any acute infections in last 7 days

• Any prior administration of immunodepressant or corticosteroids in last 6month

• Any prior administration of blood products in last 3 month

• Any prior administration of other research medicines in last 1 month

• Any prior administration of attenuated live vaccine in last 28 days

• Any prior administration of subunit or inactivated vaccines in last 14 days, such as pneumococcal vaccine

• Under the anti-TB prevention or therapy

• Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives

For infants group (aged from 6-11 months):

• Subject who has a medical history of HFMD

• <= 37 weeks gestation

• Subjects with a birth weight <2.5 kg

• Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine

• Family history of seizures or progressive neurological disease

• Family history of congenital or hereditary immunodeficiency

• Severe malnutrition or dysgenopathy

• Major congenital defects or serious chronic illness, including perinatal brain damage

• Autoimmune disease

• Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws

• Any acute infections in last 7 days

• Any prior administration of immunodepressant or corticosteroids in last 6month

• Any prior administration of blood products in last 3 month

• Any prior administration of other research medicines in last 1 month

• Any prior administration of attenuated live vaccine in last 28 days

• Any prior administration of subunit or inactivated vaccines in last 14 days, such as pneumococcal vaccine

• Under the anti-TB prevention or therapy

• Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives

Exclusion Criteria for the second dose:

• Had any Grade 3 or Grade 4 adverse reaction within 7 days after first dose

• Any situation meet the exclusion criteria stated in the exclusion criteria for first dose

• Had any SAE related to first dose during the following-up of first dose

• Any condition that in the opinion of the investigator, or IRB

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Immunogenicity
• Safety

Intervention

Biological:
• 160U /0.5ml EV71 Vaccine
inactivated vaccine (vero cell) against EV71 of 160U /0.5ml, two doses, 28 days interval
• 320U /0.5ml EV71 vaccine
inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 28 days interval
• 640U /0.5ml EV71 vaccine
inactivated vaccine (vero cell) against EV71 of 640U /0.5ml, two doses, 28 days interval
• (without adjuvant) 640U /0.5ml
inactivated vaccine (vero cell) against EV71 of (without adjuvant) 640U /0.5ml, two doses, 28 days interval
• 0/0.5ml placebo
0/0.5ml placebo, two doses, 28 days interval

Locations

Country	Name	City	State
China	Jiangsu Provincial Center for Diseases Control and Prevention	Nanjing	Jiangsu

Sponsors (2)

Lead Sponsor	Collaborator
Jiangsu Province Centers for Disease Control and Prevention	Bejing Vigoo Biological Co., LTD

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The GMT of anti-EV71 antibodies in serum after first vaccination	to evaluate the GMT of anti-EV71 antibodies in serum 28 days after first vaccination	28 days after first vaccination	No
Primary	The GMT of anti-EV71 antibodies in serum after second vaccination	to evaluate the GMT of anti-EV71 antibodies in serum 28 days after second vaccination	28 days after second vaccination	No
Primary	Frequency of systemic and local adverse reactions after the first vaccination	Frequency of systemic and local adverse reactions in healthy Children and infants following first doses of EV71 vaccine	28 days after the first vaccination	Yes
Primary	Frequency of systemic and local adverse reactions after the second vaccination	Frequency of systemic and local adverse reactions in healthy Children and infants following second doses of EV71 vaccine	28 days after the second vaccination	Yes
Secondary	The seroconversion rate of anti-EV71 antibodies in serum after first vaccination	to evaluate the seroconversion rate of anti-EV71 antibodies in serum 28 days after first vaccination	28 days after first vaccination	No
Secondary	The seroconversion rate of anti-EV71 antibodies in serum after second vaccination	to evaluate the seroconversion rate of anti-EV71 antibodies in serum 28 days after second vaccination	28 days after second vaccination	No
Secondary	Frequency of adverse events and any SAE after the first vaccination	Frequency of adverse events and any SAE in healthy Children and infants following first doses of EV71 vaccine	28 days after the first vaccination	Yes
Secondary	Frequency of adverse events and any SAE after the second vaccination	Frequency of adverse events and any SAE in healthy Children and infants following second doses of EV71 vaccine	28 days after the second vaccination	Yes
Secondary	The clinical abnormality of hematological examination, blood biochemical test and urinalysis after first vaccination in children	to evaluate the clinical abnormality of hematological examination, blood biochemical test and urinalysis 3 days after first vaccination in children	3 days after first vaccination	Yes
Secondary	The clinical abnormality of hematological examination, blood biochemical test and urinalysis after second vaccination in children	to evaluate the clinical abnormality of hematological examination, blood biochemical test and urinalysis 3 days after second vaccination in children	3 days after second vaccination	Yes
Secondary	The persistence of immunogenicity of the EV71vaccine after two doses in children and infants	to evaluate the persistence of immunogenicity of the EV71vaccine after two doses in children and infants 6 months after blood collection at day 56	6 months after blood collection at day 56	No